logo
Intelligence
Tracking
Tools
logo
Intelligence
Tracking
Tools

Senda Biosciences Announces Close Of $123 Million Series C Financing

Aug 16, 2022•over 3 years ago

Amount Raised

$123 Million

Round Type

series c

CambridgeVenture Capital

Description

Senda Biosciences, Inc., a company that is harnessing nature to program targeted, potent, and tunable medicines, today announced the completion of a $123 million Series C financing, bringing its total funding raised to date to $266 million. Flagship Pioneering, which founded Senda, participated along with new investors, including the Samsung Life Science Fund, Qatar Investment Authority (QIA), Bluwave Capital, and Stage 1 Ventures. Also participating in the financing are current investors, including Alexandria Venture Investments, Longevity Vision Fund, Mayo Clinic, Partners Investment, and State of Michigan Retirement System.

Company Information

Company

Senda Biosciences

Location

Cambridge, Maryland, United States

About

Senda Biosciences, Inc. is committed to bringing life-changing treatments to patients by harnessing millennia of evolution to program human cells both within and to the cell. Senda’s proprietary platform is the first to leverage a universal chemical routing code of natural nanoparticles that enable cross- kingdom intercellular communication. This platform unlocks comprehensive programming of medicines for the first time, allowing Senda to develop a new class of SendRNATM medicines focused initially on powering new frontiers in immunology mRNA-based therapies, with future applications employing other information molecules, including siRNA, gene editors, proteins, and peptides. Headquartered in Cambridge, Massachusetts, Senda was founded by Flagship Pioneering. For more information, visit www.sendabiosciences.com.

Related People

1 contact

Sign in to view contact details

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech